Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Kyverna Therapeutics
(NASDAQ:KYTX)
Intraday
$15.87
0.37
[2.39%]
After-Hours
$15.87
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$15.87
0.37
[2.39%]
At close: May 15
$15.87
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Q1 2024 Earnings were released on Tue May 14th, after the market close
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Kyverna Therapeutics Stock (NASDAQ:KYTX)
Kyverna Therapeutics Stock (NASDAQ: KYTX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, May 14, 2024
Kyverna Therapeutics Q1 2024 Adj EPS $(1.12) Misses $(0.84) Estimate
Benzinga Newsdesk
-
1 day ago
Monday, April 29, 2024
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Apr 29, 2024, 1:04PM
Thursday, April 11, 2024
Kyverna Therapeutics To Attend The 2024 AAN Annual Meeting With Data On KYV-101 In Treatment Of Patients With Neurological Autoimmune Diseases
Benzinga Newsdesk
-
Apr 11, 2024, 5:16PM
Monday, April 01, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Apr 1, 2024, 4:31PM
Tuesday, March 26, 2024
Kyverna Therapeutics FY23 EPS $(89.61) Vs $(63.43) YoY
Benzinga Newsdesk
-
Mar 26, 2024, 4:20PM
Friday, March 08, 2024
Kyverna Therapeutics And Stanford University Collaborate To Evaluate KYV-101 In Patients With Non-Relapsing And Progressive Forms Of Multiple Sclerosis
Benzinga Newsdesk
-
Mar 8, 2024, 2:20AM
Monday, March 04, 2024
JP Morgan Initiates Coverage On Kyverna Therapeutics with Overweight Rating, Announces Price Target of $39
Benzinga Newsdesk
-
Mar 4, 2024, 6:26AM
Morgan Stanley Initiates Coverage On Kyverna Therapeutics with Overweight Rating, Announces Price Target of $40
Benzinga Newsdesk
-
Mar 4, 2024, 6:08AM
Thursday, February 08, 2024
Kyverna Therapeutics IPO Shares Open For Trade At $34.25; IPO Priced At $22/Share On 14.5M Shares
Benzinga Newsdesk
-
Feb 8, 2024, 1:37PM
IPO For Kyverna Therapeutics Is Open For Quotation
Benzinga Newsdesk
-
Feb 8, 2024, 11:59AM
Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation
Benzinga Newsdesk
-
Feb 8, 2024, 10:10AM
Kyverna Therapeutics Prices Upsized Initial Public Offering 14.5M Common Shares At $22/Share
Benzinga Newsdesk
-
Feb 8, 2024, 2:49AM
Wednesday, February 07, 2024
Kyverna Therapeutics, Inc To Start Trading Tomorrow
Benzinga Insights
-
Feb 7, 2024, 10:00AM
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch